Dr. Cohen on Immunotherapy Combinations in Head and Neck Cancer

Ezra Cohen, MD
Published: Thursday, Dec 21, 2017



Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy combinations in head and neck cancer.

Combinations that incorporate IDO inhibitors, STAT-3 inhibitors, and anti-KIR monoclonal antibodies, are doubling and even tripling response rates in patients with head and neck cancer, says Cohen.
SELECTED
LANGUAGE


Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy combinations in head and neck cancer.

Combinations that incorporate IDO inhibitors, STAT-3 inhibitors, and anti-KIR monoclonal antibodies, are doubling and even tripling response rates in patients with head and neck cancer, says Cohen.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x